✦ LIBER ✦

Soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome following allogeneic stem cell transplantation

✍ Scribed by G.A. Yanik; J.P. Uberti; J.L.M. Ferrara; J.E. Levine; R.J. Hutchinson; V.T. Ho; K.R. Cooke

Book ID: 116277723
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 59 KB
Volume: 10
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2003.12.187

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Soluble Tumor Necrosis Factor Receptor:

Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation

✍ Gregory A. Yanik; Shin Mineishi; John E. Levine; Carrie L. Kitko; Eric S. White; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 275 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol

✍ Yanik, Gregory A.; Horowitz, Mary M.; Weisdorf, Daniel J.; Logan, Brent R.; Ho, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Recombinant human soluble tumor necrosis

Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

✍ Alessandro Busca; Franco Locatelli; Filippo Marmont; Cristina Ceretto; Michele F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

## Abstract Etanercept is a recombinant human soluble tumor necrosis factor (TNF‐α) receptor fusion protein that inhibits TNF‐α, a major mediator in the pathogenesis of graft‐versus‐host disease (GVHD). The purpose of our study was to evaluate the safety and efficacy of etanercept therapy in 21 pat

Competitive TNF Inhibitor (ETANERCEPT) f

Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT). A Joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Childrens Oncology Group (COG) Study

✍ Yanik, Gregory; Grupp, Stephan; Pulsipher, Michael A.; Levine, John E.; Schultz, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 214 KB

Prognostic value of serum surfactant pro

Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation

✍ Nakane, T; Nakamae, H; Kamoi, H; Koh, H; Takeoka, Y; Sakamoto, E; Kanashima, H; 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 163 KB

108A role for the P75 but not the P55 TN

108A role for the P75 but not the P55 TNFα receptor in the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation

✍ K.R. Cooke; K. Olkiewicz; N. Erickson; G. Hildebrandt; C. Liu; J.L. Ferrara 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 146 KB